Breast Center, Dept. OB&GYNLMU University Hospital, Munich, Germany, United States
2: Phase 3 study of neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756
Friday, March 22, 20241:14pm – 1:26pm ET